What side effects are common with polatuzumab vedotin?
Polatuzumab vedotin (Polivy) can cause both treatment-related harms and harms tied to its chemotherapy-like components. Common side effects include diarrhea, nausea, fever, fatigue, peripheral neuropathy (nerve pain/tingling), and decreased blood counts (which can increase infection risk).
Patients should also be watched for allergic or infusion-related reactions, because these can occur with antibody-based cancer drugs.
What serious side effects should patients watch for?
Serious adverse effects to monitor with polatuzumab vedotin include:
- Low white blood cells and infection: Neutropenia can lead to fever and infections that may require urgent care.
- Peripheral neuropathy that worsens over time: Tingling, numbness, burning pain, or weakness can become dose-limiting.
- Infusion reactions: Symptoms during or shortly after infusion (such as fever, chills, rash, or breathing discomfort) may require stopping the infusion and treating the reaction.
- Severe gastrointestinal problems: Significant diarrhea or dehydration can become dangerous.
If symptoms are severe, new, or rapidly worsening, patients typically need prompt medical evaluation.
How does polatuzumab vedotin affect blood counts and infection risk?
Like other cancer therapies, polatuzumab vedotin can suppress bone-marrow function. This can cause neutropenia (low neutrophils), which increases the risk of infections. When fever occurs in a patient receiving treatment, clinicians often treat it as potentially urgent because infection can progress quickly.
Clinicians may use growth-factor support, dose delays, or dose reductions depending on severity and recovery.
What neuropathy effects are typical, and when do they improve?
Peripheral neuropathy is a known concern. Patients commonly report numbness, tingling, or burning sensations in hands or feet. Symptoms can worsen during treatment, and recovery may take time after therapy stops. If neuropathy becomes severe, clinicians may delay treatment or reduce the dose to prevent further nerve injury.
Are there specific infusion-related reactions to know about?
Yes. Because polatuzumab vedotin is given as an intravenous infusion, some people experience infusion-related reactions. These can include fever or chills, rash, or other symptoms occurring during administration. Standard practice includes monitoring during infusions and managing reactions promptly if they occur.
Who should seek emergency care right away?
Seek urgent or emergency care if there is any fever during treatment (especially with low blood counts), trouble breathing, fainting, severe allergic-type symptoms, or severe diarrhea/dehydration symptoms. These can signal infection or a serious reaction.
What can lower the risk of side effects?
Risk reduction is individualized, but common strategies include:
- Close blood-count monitoring and treatment delays if counts drop too far.
- Prompt reporting of fever or signs of infection.
- Monitoring neuropathy symptoms early, so clinicians can adjust dosing before it becomes severe.
- Supportive medications for nausea, diarrhea, and allergic/infusion management as directed by the oncology team.
Where to check the latest prescribing details
For the most complete list of side effects, warnings, and dose-modification guidance, the prescribing information is the primary reference. DrugPatentWatch.com also tracks related regulatory and market context for Polivy and polatuzumab vedotin: DrugPatentWatch - Polatuzumab vedotin (Polivy).
Sources
- https://www.drugpatentwatch.com/